Profile data is unavailable for this security.
About the company
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. The Company is focused on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology. The Company has two divisions: Medexus Pharma Canada and Medexus Pharma USA. Medexus Pharma Canada division is a fully integrated commercial infrastructure focused on rheumatology, allergy, auto-immune disease, specialty oncology and pediatric diseases in Canada. The division’s prescription products include Metoject (Methotrexate Injection), Rupall (Rupatadine), Cuvposa (Glycopyrrolate Oral Solution), Pediapharm Naproxen Suspension (Naproxen) and others. Medexus Pharma USA division is a fully integrated commercial infrastructure focused on rheumatology and auto-immune diseases in the United States. The division’s products include Rasuvo, IXINITY and Gleolan.
- Revenue in CAD (TTM)147.49m
- Net income in CAD1.48m
- Incorporated2021
- Employees98.00
- LocationMedexus Pharmaceuticals Inc10 King Street East, Suite 600TORONTO M5C 1C3CanadaCAN
- Phone+1 (514) 762-2626
- Websitehttps://www.medexus.com/en_US
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Decibel Cannabis Company Inc | 101.04m | -563.00k | 30.68m | -- | -- | 0.7122 | 9.34 | 0.3036 | -0.0016 | -0.0096 | 0.2349 | 0.1053 | 0.7555 | 1.28 | 6.86 | -- | -0.421 | -3.55 | -0.6781 | -5.19 | 42.57 | 38.83 | -0.5572 | -7.13 | 0.3644 | 1.90 | 0.5178 | -- | 46.18 | -- | 60.33 | -- | -32.45 | -- |
| Simply Solventless Concentrates Ltd | -100.00bn | -100.00bn | 37.40m | -- | -- | 3.79 | -- | -- | -- | -- | -- | 0.1293 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.1873 | -- | 0.2432 | -- | -- | -- | -- | -- | -- | -- |
| Medicus Pharma Ltd | 0.00 | -15.91m | 49.51m | -- | -- | 5.66 | -- | -- | -1.73 | -1.73 | 0.00 | 0.4032 | 0.00 | -- | -- | -- | -267.24 | -652.37 | -371.17 | -- | -- | -- | -- | -- | -- | -20.26 | 0.0549 | -- | -- | -- | -300.86 | -- | -- | -- |
| Auxly Cannabis Group Inc | 109.54m | -45.41m | 50.13m | 369.00 | -- | 0.4715 | -- | 0.4576 | -0.0452 | -0.0452 | 0.1012 | 0.0848 | 0.3794 | 2.26 | 6.32 | 296,853.70 | -15.73 | -21.47 | -22.88 | -24.99 | 12.67 | 5.08 | -41.45 | -124.15 | 0.4187 | -1.41 | 0.4279 | -- | 6.99 | 166.85 | 65.84 | -- | -40.92 | -- |
| LSL Pharma Group Inc | 14.32m | -2.03m | 54.30m | -- | -- | 2.70 | -- | 3.79 | -0.0232 | -0.0232 | 0.1612 | 0.1743 | 0.4307 | 2.28 | 6.06 | -- | -6.12 | -- | -8.70 | -- | 22.68 | -- | -14.20 | -- | 0.4909 | -0.3722 | 0.4126 | -- | -- | -- | -- | -- | -- | -- |
| Medexus Pharmaceuticals Inc | 147.49m | 1.48m | 60.94m | 98.00 | 51.61 | 1.38 | 6.55 | 0.4132 | 0.0483 | 0.0483 | 6.31 | 1.81 | 0.6926 | 1.69 | 5.55 | -- | 0.6952 | -5.03 | 1.33 | -7.77 | 52.50 | 53.26 | 1.00 | -8.05 | 0.4928 | 1.39 | 0.5897 | -- | 4.59 | 34.37 | -117.53 | -- | -9.45 | -- |
| Theratechnologies Inc | 111.95m | -9.48m | 75.61m | 103.00 | -- | -- | -- | 0.6754 | -0.2519 | -0.2519 | 2.88 | -0.6843 | 1.19 | 2.70 | 6.36 | 1,086,891.00 | -10.07 | -26.32 | -89.40 | -55.43 | 75.94 | 65.90 | -8.47 | -38.26 | 0.9963 | 0.4497 | 1.64 | -- | 2.13 | 12.58 | 49.28 | -- | -37.83 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 31 Jan 2024 | 1.54m | 6.26% |
| Perritt Capital Management, Inc.as of 30 Apr 2024 | 135.10k | 0.55% |
| Goodwood, Inc.as of 31 Dec 2023 | 66.02k | 0.27% |
